Novel monoclonal antibody-use to treat rheumatoid arthritis
Treatment with the novel monoclonal antibody mavrilimumab
was associated with decreased disease activity and high rates of clinical
responses in patients with moderate-to-severe rheumatoid arthritis (RA), a
phase IIb study found.
"Data from this study demonstrate that mavrilimumab, particularly
at a dosage of 150 mg every other week, provides a rapid, effective, and
well-tolerated potential treatment for patients with rheumatoid
arthritis," they observed.
Mavrilimumab blocks the receptor for granulocyte-macrophage
colony-stimulating factor (GM-CSF), a proinflammatory cytokine that is involved
in the activation and differentiation of neutrophils, dendritic cells, and
macrophages and that has been detected in the synovial fluid and tissues of
patients with RA.
No comments:
Post a Comment